8-K: Collegium Pharmaceutical Announces $35 Million Accelerated Share Repurchase

Collegium Pharmaceutical has entered into an accelerated share repurchase agreement with Jefferies LLC to buy back $35 million of its common stock as part of a larger $150 million program.

Summary

• Collegium Pharmaceutical has initiated an accelerated share repurchase (ASR) program to buy back $35 million of its common stock.
• The ASR agreement is with Jefferies LLC and is part of a $150 million share repurchase program authorized in January 2024.
• The company will pay $35 million to Jefferies LLC and receive an initial delivery of 888,889 shares.
• This initial delivery is based on a closing stock price of $31.50 on May 10, 2024, and represents about 80% of the expected total shares to be repurchased.
• The final number of shares repurchased will depend on the volume-weighted average price of the stock during the ASR term.
• The final settlement of the ASR is expected to be completed in the third quarter of 2024.
• As of March 31, 2024, Collegium had approximately 32.7 million shares outstanding.

Sentiment

Score: 7

Explanation: The announcement of a share repurchase program is generally viewed positively by investors, indicating management's confidence in the company's future prospects and a commitment to returning value to shareholders. However, the final number of shares is subject to market conditions, which introduces some uncertainty.

Positives

• The share repurchase program signals management's confidence in the company's value.
• The ASR is part of a larger $150 million program, indicating a significant commitment to returning value to shareholders.
• The initial delivery of shares is substantial, representing approximately 80% of the expected total.

Risks

• The final number of shares repurchased is subject to market fluctuations and the volume-weighted average price of the stock.
• The company's actual results may differ from expectations due to various factors, including market conditions.
• There are risks associated with changes in the securities markets and fluctuations in the trading volume and market price of the company's common stock.

Future Outlook

The company expects the final settlement of the ASR agreement to be completed in the third quarter of 2024, but the final number of shares repurchased will depend on market conditions.

Management Comments

• The company is executing the ASR agreement as part of the $150 million share repurchase program authorized by its Board of Directors.

Industry Context

Share repurchase programs are a common method for companies to return value to shareholders, especially when they believe their stock is undervalued. This move by Collegium is consistent with broader trends in capital allocation among publicly traded companies.

Comparison to Industry Standards

• Many pharmaceutical companies use share repurchase programs to manage their capital structure and enhance shareholder value.
• The size of the program, $150 million, is significant for a company of Collegium's size, indicating a strong commitment to returning capital to shareholders.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) have also engaged in share repurchase programs, though the specific terms and amounts vary based on their financial situations and market conditions.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program, which may increase the value of their holdings.
• The program may also signal confidence to other stakeholders, such as employees and creditors.

Next Steps

• The company will continue to execute the ASR agreement.
• The final settlement of the ASR is expected in the third quarter of 2024.

Key Dates

Keywords

share repurchase, accelerated share repurchase, ASR, stock buyback, capital allocation, Jefferies LLC, common stock